Immune Design (NASDAQ:IMDZ)‘s stock had its “buy” rating reissued by research analysts at Cowen in a report released on Monday.

Several other equities analysts also recently commented on the stock. Wells Fargo & Company downgraded shares of Immune Design from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $29.00 to $10.00 in a research note on Tuesday, October 17th. ValuEngine downgraded shares of Immune Design from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 21st. Zacks Investment Research downgraded shares of Immune Design from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Finally, Royal Bank of Canada initiated coverage on shares of Immune Design in a research note on Thursday, September 14th. They set an “outperform” rating and a $20.00 price objective for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $13.19.

Immune Design (NASDAQ:IMDZ) traded down $0.25 during midday trading on Monday, reaching $3.70. 595,500 shares of the company’s stock traded hands, compared to its average volume of 313,584. Immune Design has a twelve month low of $3.55 and a twelve month high of $13.05.

Immune Design (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.11. The firm had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.62 million. Immune Design had a negative net margin of 619.62% and a negative return on equity of 68.69%. equities research analysts anticipate that Immune Design will post -1.89 EPS for the current year.

In related news, Director Franklin M. Berger purchased 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The stock was bought at an average cost of $4.58 per share, with a total value of $114,500.00. Following the completion of the purchase, the director now directly owns 75,000 shares in the company, valued at $343,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lewis W. Coleman purchased 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The stock was bought at an average cost of $4.50 per share, with a total value of $225,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 5,300,000 shares of company stock valued at $21,874,900. 20.70% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in IMDZ. Bank of America Corp DE grew its holdings in Immune Design by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 8,418 shares during the period. State of Wisconsin Investment Board purchased a new stake in Immune Design in the second quarter worth about $117,000. Alliancebernstein L.P. purchased a new stake in Immune Design in the second quarter worth about $118,000. Virtu KCG Holdings LLC purchased a new stake in Immune Design in the second quarter worth about $153,000. Finally, Dimensional Fund Advisors LP grew its holdings in Immune Design by 9.3% in the second quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 1,600 shares during the period. Institutional investors and hedge funds own 29.38% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/12/immune-design-imdz-earns-buy-rating-from-cowen.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.